-
Mashup Score: 0FDA approval sought for darolutamide in mHSPC - 2 year(s) ago
The filing is based on findings from the placebo-controlled phase 3 ARASENS trial.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0
“In our cohort, [diabetes mellitus] was a significant predictor of lower [erectile function recovery] at 2 years post-RP,” the authors wrote.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0
“In our cohort, [diabetes mellitus] was a significant predictor of lower [erectile function recovery] at 2 years post-RP,” the authors wrote.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0
“In our cohort, [diabetes mellitus] was a significant predictor of lower [erectile function recovery] at 2 years post-RP,” the authors wrote.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
FDA supplemental new drug application filed for darolutamide in mHSPC https://t.co/BuTs9Y8vqc #MHSPC #ProstateCance #Urology #Urologist